Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BIVI |
---|---|---|
09:32 ET | 11562 | 0.4925 |
09:34 ET | 200 | 0.49 |
09:38 ET | 5691 | 0.49 |
09:39 ET | 2817 | 0.49 |
09:41 ET | 400 | 0.49 |
09:52 ET | 1092 | 0.49 |
09:56 ET | 2190 | 0.49 |
09:57 ET | 2640 | 0.4949 |
09:59 ET | 2040 | 0.4902 |
10:01 ET | 6543 | 0.4949 |
10:03 ET | 2100 | 0.4951 |
10:06 ET | 200 | 0.4951 |
10:10 ET | 100 | 0.4901 |
10:17 ET | 101 | 0.4919 |
10:26 ET | 100 | 0.492 |
10:28 ET | 4500 | 0.4976 |
10:30 ET | 700 | 0.49565 |
10:37 ET | 200 | 0.4966 |
10:42 ET | 1606 | 0.4979 |
10:46 ET | 4699 | 0.4941 |
10:48 ET | 4256 | 0.49335 |
10:51 ET | 630 | 0.4934 |
11:00 ET | 100 | 0.4957 |
11:04 ET | 1100 | 0.4957 |
11:06 ET | 6590 | 0.49655 |
11:08 ET | 2508 | 0.49655 |
11:09 ET | 100 | 0.4979 |
11:13 ET | 100 | 0.4965 |
11:15 ET | 100 | 0.4965 |
11:20 ET | 2981 | 0.4969 |
11:22 ET | 968 | 0.4969 |
11:24 ET | 200 | 0.4969 |
11:27 ET | 800 | 0.4932 |
11:29 ET | 13808 | 0.4925 |
11:33 ET | 120 | 0.4901 |
11:38 ET | 2600 | 0.490101 |
11:40 ET | 1100 | 0.4925 |
11:42 ET | 200 | 0.492501 |
11:45 ET | 100 | 0.4901 |
11:47 ET | 100 | 0.4925 |
11:54 ET | 100 | 0.4948 |
12:02 ET | 627 | 0.4902 |
12:03 ET | 200 | 0.4942 |
12:09 ET | 415 | 0.494 |
12:12 ET | 1200 | 0.494 |
12:16 ET | 100 | 0.4949 |
12:20 ET | 100 | 0.494 |
12:21 ET | 100 | 0.4945 |
12:25 ET | 699 | 0.4941 |
12:27 ET | 400 | 0.49411 |
12:32 ET | 2678 | 0.495 |
12:34 ET | 900 | 0.4969 |
12:36 ET | 200 | 0.4941 |
12:41 ET | 5892 | 0.4955 |
12:43 ET | 2769 | 0.496 |
12:48 ET | 1000 | 0.494 |
12:50 ET | 213 | 0.4941 |
12:54 ET | 9604 | 0.4955 |
12:56 ET | 5254 | 0.4969 |
12:57 ET | 1200 | 0.4942 |
12:59 ET | 100 | 0.4955 |
01:03 ET | 300 | 0.4955 |
01:06 ET | 800 | 0.4955 |
01:10 ET | 100 | 0.49595 |
01:14 ET | 200 | 0.4968 |
01:19 ET | 200 | 0.4968 |
01:21 ET | 500 | 0.495 |
01:24 ET | 100 | 0.4959 |
01:30 ET | 1000 | 0.4959 |
01:32 ET | 100 | 0.495 |
01:33 ET | 100 | 0.4959 |
01:37 ET | 300 | 0.495 |
01:39 ET | 710 | 0.4959 |
01:46 ET | 2600 | 0.4967 |
01:48 ET | 297 | 0.4965 |
01:50 ET | 29988 | 0.4935 |
01:51 ET | 851 | 0.4935 |
01:53 ET | 2207 | 0.4914 |
02:09 ET | 815 | 0.491351 |
02:11 ET | 2693 | 0.4897 |
02:29 ET | 200 | 0.49 |
02:33 ET | 747 | 0.4898 |
02:40 ET | 400 | 0.4906 |
02:42 ET | 1666 | 0.4917 |
02:47 ET | 100 | 0.4897 |
02:51 ET | 100 | 0.4897 |
02:56 ET | 100 | 0.4897 |
03:00 ET | 350 | 0.48995 |
03:03 ET | 108 | 0.49 |
03:05 ET | 200 | 0.4899 |
03:07 ET | 786 | 0.49 |
03:12 ET | 300 | 0.49 |
03:14 ET | 200 | 0.49 |
03:16 ET | 200 | 0.49 |
03:18 ET | 511 | 0.49 |
03:20 ET | 100 | 0.48995 |
03:21 ET | 200 | 0.4902 |
03:23 ET | 400 | 0.4899 |
03:25 ET | 1250 | 0.49 |
03:27 ET | 600 | 0.4912 |
03:30 ET | 1200 | 0.4899 |
03:32 ET | 100 | 0.49235 |
03:36 ET | 3990 | 0.4884 |
03:41 ET | 3300 | 0.48915 |
03:43 ET | 100 | 0.4892 |
03:45 ET | 100 | 0.4905 |
03:50 ET | 182 | 0.4913 |
03:52 ET | 100 | 0.4892 |
03:54 ET | 200 | 0.4892 |
03:56 ET | 300 | 0.4892 |
03:57 ET | 500 | 0.4905 |
03:59 ET | 1960 | 0.4918 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioVie Inc | 30.0M | -0.5x | --- |
Apollomics Inc | 29.7M | -0.1x | --- |
Surrozen Inc | 30.5M | -0.5x | --- |
Janone Inc | 30.7M | -0.9x | --- |
Viracta Therapeutics Inc | 31.7M | -0.7x | --- |
RenovoRx Inc | 32.8M | -1.9x | --- |
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-0.96 |
Book Value | $0.42 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.